Common Questions in Crohn s Disease Therapy. Case
|
|
- Nathaniel Ford
- 5 years ago
- Views:
Transcription
1 Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound weight loss. Exam notable for right sided abdominal tenderness Labs: WBC- 11.9; Hg- 9.1; MCV- 69; PLT- 610 Alb- 3.6; LFTs normal ESR & CRP- normal Stool studies negative for infection Copyright 2015 American College of Gastroenterology 1
2 Case CTe- 15 cm of TI inflammation Started on prednisone with good response Now returns for follow up What therapy now? Copyright 2015 American College of Gastroenterology 2
3 Questions in Maximizing Therapy for Crohn s What is the overall treatment goal? Single or combination treatment? Same approach for everyone? For how long? How can we maximize therapy? When do we switch therapies? Questions in Maximizing Therapy for Crohn s What is the overall treatment goal? Single or combination treatment? Same approach for everyone? For how long? How can we maximize therapy? When do we switch therapies? Copyright 2015 American College of Gastroenterology 3
4 Potential Treatment Goals in Crohn s Symptom improvement Avoid fistulizing/stricturing complications Minimize hospitalization Avoid/minimize surgery Mucosal healing Histologic healing Does achieving mucosal healing mean anything? YES! Copyright 2015 American College of Gastroenterology 4
5 Mucosal healing has been associated with: Decreased need for corticosteroids Decreased hospitalization rates Sustained clinical remission Decreased surgery rates Baert F, et al. Gastroenterology 2010;138:463-8 Copyright 2015 American College of Gastroenterology 5
6 Long-term Outcomes Following Mucosal Healing: Belgium Cohort study of 214 CD patients on IFX, followed for median of > years Colonoscopy done before and at median of 6.7 months after starting IFX Complete MH 45.4%, Partial MH 22.4%, MH was associated with: Better disease free survival (P<0.001) Avoiding major abdominal surgery (14% vs 38%, P<0.05) Fewer hospitalizations (42% vs 59%, P<0.05) Schnitzler F, et al. Inflamm Bowel Dis 2010;15: Questions in Maximizing Therapy for Crohn s What is the overall treatment goal? Single or combination treatment? Same approach for everyone? For how long? How can we maximize therapy? When do we switch therapies? Copyright 2015 American College of Gastroenterology 6
7 Top Down vs Step Up Study Patients yo with: Dx of Crohn s within past 4 years and NO prior steroids, antimetabolites, or biologics CDAI > 200 for > 2 weeks On average CD was diagnosed less than 4 months before randomization in study participants Randomized to: Early combined immunosuppression Conventional treatment Primary analysis- Remission rates at weeks 26 & 52 D Haens, G. Lancet 2008;371:660-7 Early combined immunosuppression Infliximab- 5 mg/kg g at 0, 2 & 6 weeks AND Azathioprine mg/kg (MTX if intolerant) If symptoms persisted Methylprednisolone If responded but symptoms recurred: Infliximab first If still symptomatic Methylprednisolone D Haens G. Lancet 2008;371:660-7 Copyright 2015 American College of Gastroenterology 7
8 Conventional treatment Methylpred yp (32 mg) or budesonide (9 mg) with 10 week taper If symptoms persisted Methylprednisolone at 64 mg qd and azathioprine If responded but symptoms recurred: Steroids Azathioprine Infliximab D Haens G. Lancet 2008;371:660-7 CDAI < 150 & Off Steroids Copyright 2015 American College of Gastroenterology 8
9 Corticosteroid Use D Haens G. Lancet 2008;371:660-7 Mucosal Healing at 2 years Early Immunosupp P= Conventional Tx D Haens G. Lancet 2008;371:660-7 Copyright 2015 American College of Gastroenterology 9
10 SONIC Trial Main Extension Visitsit Week 0* Week 2 Week 6 Week 10 Week 14 Week 18 Week 22 Week 26* Week 30 Week 38 Week 42 Week 46 Week 50 Week 54 Azathioprine 2.5 mg/kg + placebo infusions Randomization of patients Infliximab 5 mg/kg + placebo capsules Infliximab 5 mg/kg + Azathioprine 2.5 mg/kg Primary Endpoint (Corticosteroid-free Remission at Week 26) Infusions Secondary Endpoint (Week 50) * Endoscopy performed at Weeks 0 & 26 Steroid-Free Clinical Remission Wk 26 Patients with CRP 0.8 mg/dl & Lesions on Baseline Endoscopy (n=204) ion of patients (%) Proport p<0.001 p< p= /75 37/65 44/64 AZA+ placebo IFX + placebo IFX + AZA Copyright 2015 American College of Gastroenterology 10
11 Mucosal Healing at Week ) Propo ortion of Patients (%) p<0.001 p=0.023 p= /109 28/93 47/107 AZA + placebo IFX + placebo IFX+ AZA Infliximab +/- Concomitant Immunomodulator in Pediatric Crohn s Grossi V. Clin Gastroenterol Hepatol 2015;13: Copyright 2015 American College of Gastroenterology 11
12 In males, MTX was superior to thiopurine as concomitant treatment Grossi V. Clin Gastroenterol Hepatol 2015;13: Immunogenicity: Week 30 Data from SONIC 15% Antibody Development (%) 15% 4 3 IFX Drug Level (ug/ml) P < % 5% % 0% IFX IFX + AZA 0 IFX IFX + AZA Copyright 2015 American College of Gastroenterology 12
13 Adalimumab 4 week Remission: CLASSIC vs GAIN 50% 40% 36% 30% 20% 10% 12% 7% 21% 0% CLASSIC (TNF naïve) Placebo GAIN (Prior IFX) ADA 160/80 mg Gastroenterology 2006;130: Ann Intern Med 2007;146: WELCOME: Certolizumab after secondary failure to infliximab 70% 60% 50% 40% 30% 20% 10% 0% 62% 48% PRECiSE 2 Wk 26 Remission 40% 29% WELCOME Wk 26 Response Schrebier S. NEJM 2007;357; Gastroenterology 2009;136(Suppl1): Abstract 143 Copyright 2015 American College of Gastroenterology 13
14 Questions in Maximizing Therapy for Crohn s What is the overall treatment goal? Single or combination treatment? Same approach for everyone? For how long? How can we maximize therapy? When do we switch therapies? Therapeutic options A B C D Immune response Early disease Late disease Copyright 2015 American College of Gastroenterology 14
15 PRECiSE 2: Response and Remission to Certolizumab pegol by Disease Duration Schreiber S. Am J Gastroenterol 2010;105: CHARM: Response by Disease Duration Wk 26 Remission 50% 50% Wk 56 Remission 40% 30% 40% 30% 20% 10% 0% < 2 yrs 2 to 4 yrs > 5 yrs Placebo 20% 10% 0% < 2 yrs 2 to 4 yrs > 5 yrs Adalimumab Schreiber S. J Crohns Colitis 2013;7: Copyright 2015 American College of Gastroenterology 15
16 Early Predictors of Aggressive Disease Course Young age at diagnosis Need for steroid therapy at diagnosis Perianal disease Extensive small bowel disease Summary: Combination therapy Advantages: Better clinical response rates Less steroid use Higher mucosal healing rates Less immunogenicity/higher drug levels More likely to continue anti-tnf agent Which patients? Early disease Aggressive disease markers Copyright 2015 American College of Gastroenterology 16
17 Questions in Maximizing Therapy for Crohn s What is the overall treatment goal? Single or combination treatment? Same approach for everyone? For how long? How can we maximize therapy? When do we switch therapies? Withdrawal of Infliximab 1-year relapse rate = 44% Louis E et al. Gastroenterology 2012;142:63-70 Copyright 2015 American College of Gastroenterology 17
18 Multivariate Model for Relapse Factor HR P Ml Male < No surgical resection hscrp > 5 mg/l Hg < 14.5 g/dl WBC > Fecal calprotectin > Louis E et al. Gastroenterology 2012;142:63-70 Immunosuppressive Withdrawal IF FX change or D/C 80% 70% 60% 50% 40% 30% 20% 10% 0% 60% 55% + IS No IS Van Assche G. Gastroenterology 2008;134: Copyright 2015 American College of Gastroenterology 18
19 Predictors of infliximab failure after azathioprine withdrawal Retrospective observational study 48 patients who had received IFX + AZA for > 6 months Predictor HR P Time of comb tx < 811 days CRP > 5 mg/l AZA D/Ced PLT > Oussalah A. Am J Gastroenterol 2010;105: Questions in Maximizing Therapy for Crohn s What is the overall treatment goal? Single or combination treatment? Same approach for everyone? For how long? How can we maximize therapy? When do we switch therapies? Copyright 2015 American College of Gastroenterology 19
20 Back to our case He is started on adalimumab at 40 mg q 2 weeks and azathioprine at 50 mg qd 6 months later- notes marked improvement in symptoms ( best I ve felt in 2 years ) but still has mild diarrhea and intermittent abdominal pain Colonoscopy shows improvement but there are still scattered superficial ulcers in terminal ileum. Utility of drug levels in adjusting therapy Copyright 2015 American College of Gastroenterology 20
21 6-MP Metabolism 6-Methyl Methyl-Mercaptopurine Mercaptopurine (6-MMP) TPMT Azathioprine 6-MP HPRT Thioinosinic Acid 6-Thioguanine nucleotides (6-TGN) XO 6-Thiouric Acid Meta-Analysis: Correlation of 6-TGN threshold and remission Osterman MT. Gastroenterology 2006;130: Copyright 2015 American College of Gastroenterology 21
22 Non-Response to 6-MP Study of 51 IBD patients failing therapy with 6-MP or AZA 6-MP metabolite levels measured before and after dose escalation: 14 patients (27%) responded clinically 37 patients had no clinical benefit Effect of Dose Escalation on 6-TGN Levels 900 P = RBC) level (pmols/8 x TGN Time 0 Time 1 Time 0 Time 1 Non-Responders Responders Dubinsky et al. Gastroenterology 2002;112:904. Copyright 2015 American College of Gastroenterology 22
23 Metabolite Monitoring in Non-Responders Identify reasons for non-response: 6-TGN 6-MMP Inadequate dose Non-adherence 0 6-MMP shunting Drug resistance Utility of Infliximab Levels & Antibodies Medical records of 155 IBD pts who had antibodies & levels drawn in clinical practice ATIs (23%) change to another anti-tnf led to complete/partial response in 92% Low infliximab (44%) dose escalation led to complete/partial e/p response se in 86% Therapeutic infliximab (33%) no evidence of active inflammation in 62% Afif W, et al. Am J Gastroenterol 2010;105: Copyright 2015 American College of Gastroenterology 23
24 Drug and antibody levels in guiding inteventions after loss of response Study of 247 patients who developed loss of response to infliximab or adalimumab Adalimumab: Trough drug level > 4.5 mcg/ml: 90% specificity for no response to dose intensification Predictive of response to either NO change in tx OR to change out-of-class tx Antibody level > 4 mcg/ml: 90% specificity for failure to respond to dose intensification Yanai H. Clin Gastroenterol Hepatol 2015;13: Drug and antibody levels in guiding inteventions after loss of response Infliximab: Trough drug level > 3.8 mcg/ml: 90% specificity for no response to dose intensification Predictive of response to either NO change in tx OR to change out-of-class tx Antibody level > 9 mcg/ml: 90% specificity for failure to respond to dose intensification Shorter duration of response after regained response Yanai H. Clin Gastroenterol Hepatol 2015;13: Copyright 2015 American College of Gastroenterology 24
25 Drug level correlates with mucosal healing Ungar B. Clin Gastroenterol Hepatol 2015; in press Effect of Antibody Positivity on Anti-TNF response: Meta-Analysis Garces S. Ann Rheum Dis 2013;72: Copyright 2015 American College of Gastroenterology 25
26 Applying Drug/Ab Levels in loss of or non-response Low drug level Good drug level Low drug level No/low Ab level No/low Ab level High Ab level Increase anti- TNF dose?active inflammation Anti-TNF switch YES NO Out of class switch Look for non- IBD causes Putting it all together Copyright 2015 American College of Gastroenterology 26
27 Treat to Target: A Potential Approach In patients with aggressive disease start anti-tnfs + immunosuppressive early in disease course: Best effects with disease duration < 2 years Mucosal healing for CD of 44% at 26 weeks (SONIC) and 73% at 2 years (Top-Down) Assess for mucosal healing within 6 months of medication start or medication adjustment: Ed Endoscopy?surrogate markers Use drug levels & different classes of medications to guide decisions for medical tx changes Is there evidence to support such an approach? Copyright 2015 American College of Gastroenterology 27
28 35% 30% EXTEND: Deep remission rates based on duration of disease 33% 33% 25% 20% 15% 10% 5% 0% 20% 14% 16% 13% 10% 7% < 2 yrs 2-5 yrs > 5 yrs < 2 yrs 2-5 yrs > 5 yrs Week 12 Week 52 ADA Placebo Treat to Target Approach Retrospective review of 67 CD patients: Baseline endoscopy with ulcers in any GI segment AND Had at least 2 F/U endoscopies during study period Evaluated impact of medical tx changes on: Mucosal healing- absence of any ulcers Endoscopic improvement- downgrading of deep ulcers to superficial ulcers OR disappearance of superficial ulcers Bouguen G. Clin Gastroenterol Hepatol 2014;12: Copyright 2015 American College of Gastroenterology 28
29 Median F/U duration 62 wks (44-79) # of F/U endoscopies: Follow-Up 67 (100%) 21 (31%) 6 (9%) Median time between 1 st 2 procedures 24 wks (17-38) Cumulative Probability of MH/Improvement: 24 weeks 56 weeks Changes in medical therapy: Anti-TNF started Anti-TNF dose optimized Switch to another anti-tnf Immunosuppressive started Switch to ustekinumab 13%/15% 45%/54% N Bouguen G. Clin Gastroenterol Hepatol 2014;12: Multivariate Analysis for Endoscopic Outcomes Endoscopic Outcome OR (95% CI) Mucosal Healing: Adjustment of medical therapy 359( ( ) 40) Endoscopic improvement: Adjustment of medical therapy Endo procedures within 26 wks 2.08 ( ) 1.95 ( ) Discrepancy between clinical symptoms & endo inflammation: 41% had symptoms despite mucosal healing (all w/ nl CRP) 19% w/ significant endoscopic lesions had no clinical symptoms Bouguen G. Clin Gastroenterol Hepatol 2014;12: Copyright 2015 American College of Gastroenterology 29
30 Cost Effectiveness Analysis of Mucosal Healing as an Endpoint Clinical response (CR) arm- IFX dose escalation in patients not in clinical remission Mucosal healing (MH) arm- IFX dose escalation in patients without mucosal healing After 2 years, MH was more effective but more expensive- ICER $49,278 per QALY gained Ananthakrishnan AN, Inflamm Bowel Dis 2013;19:37-44 Decision Analysis Hypothetical 100,000 pt cohort in each arm CR arm vs MH arm: Dose escalations: 51,479 vs 56,686 (+5,207) Hospitalizations: 16,679 vs 12,844 (-3,835) Surgeries: 3,851 vs 2,881 (-970) Number needed to treat: Prevent 1 hospitalization NNT = 27 Prevent 1 surgery NNT = 106 Ananthakrishnan AN, Inflamm Bowel Dis 2013;19:37-44 Copyright 2015 American College of Gastroenterology 30
31 Summary Combination therapy is better than monotherapy: Clinical response/remission; less steroid use Mucosal healing Reduced immunogenicity Mucosal healing: Can be achieved in anywhere from 30-70% of patients Better outcomes in early disease Is associated with better long term outcomes With drug monitoring tests and new classes of drugs, there will be increasing options to tailor medical therapy treat to target concept Copyright 2015 American College of Gastroenterology 31
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Brian Feagan, MD, FACG Professor of Medicine and Epidemiology and Biostatistics Director, Robarts Clinical Trials Robarts Research Institute University
More informationJoin the conversation at #GIFORUMCCFA
1 Join the conversation at #GIFORUMCCFA 2 Disclosures In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationDisclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationBiologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
More informationOptimizing Immunomodulators and
Optimizing Immunomodulators and Biologics i in Inflammatory Bowel Disease Sunanda Kane, MD, MSPH, FACG Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota,
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationThe Best of IBD at UEGW (Crohn s)
The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationAli Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationAssociation Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Jean Frédéric Colombel, William J. Sandborn, Matthieu Allez, Jean Louis Dupas, Olivier
More informationLatest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker
More informationPerianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic
Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification
More informationWithdrawal of drug therapy in patients with quiescent Crohn s disease
Withdrawal of drug therapy in patients with quiescent Crohn s disease DR. JEAN-FRÉDÉRIC COLOMBEL DIRECTOR OF THE IBD CENTER, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, USA Withdrawal of drug therapy
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationAgenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease
Agenda Predictive markers in IBD Management of ulcerative colitis Management of Crohn s disease 2 Patients With UC (%) Distribution of UC Disease Severity at Presentation 1 Fulminant disease (9%) 8 6 4
More informationOPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG
1C: Advances in Inflammatory Bowel Disease OPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG narrow interpretation of this presentation topic would A be a discussion of dosing
More informationBiologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Gary R. Lichtenstein, MD, FACG Professor of Medicine Director, Inflammatory Bowel Disease Program University of Pennsylvania Philadelphia, PA In my
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationLessons to learn from Crohn's disease clinical trials: implications for ulcerative colitis
Lessons to learn from Crohn's disease clinical trials: implications for ulcerative colitis Aránzazu Jáuregui Amézaga, Elena Ricart, Julián Panés Department of Gastroenterology, Hospital Clínic de Barcelona,
More informationHow to use infliximab?
How to use infliximab? Séverine Vermeire, MD, PhD Division of Gastroenterology University Hospital Gasthuisberg Leuven The how to use infliximab rules Before starting IFX: try optimizing chances for response!
More informationTreating to Achieve a Target and Disease Monitoring in 2015: State of the Art
Treating to Achieve a Target and Disease Monitoring in 2015: State of the Art David T. Rubin, MD The Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationUpdate on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
More informationWhen can I stop taking my medications? Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida
When can I stop taking my medications? Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Post-op low risk patient Uc de-escalation Discuss combo therapy Which one worked IBD
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationThe Refractory Crohn s Disease
The Refractory Crohn s Disease Patient David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationEndpoints for Stopping Treatment in UC
Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh
More informationMucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
More informationCrohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?
Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation? Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic
More information5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD
5/2/218 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD Grant support for preclinical studies: Janssen, Gusto Global, Vedanta, Artizan BALFOUR SARTOR, MD DISTINGUISHED
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationOptimizing the effectiveness of anti-tnf therapy in paediatric IBD
Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of
More informationAvailable Data on Pediatric Exposure Response a Clinician s Perspective
Available Data on Pediatric Exposure Response a Clinician s Perspective Marla Dubinsky, MD Professor of Pediatrics and Medicine Chief Pediatric GI and Nutrition Co-Director Susan and Leonard Feinstein
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationImmunogenicity of Biologic Agents and How to Prevent Sensitization
Immunogenicity of Biologic Agents and How to Prevent Sensitization William J. Sandborn, MD Professor and Chief, Division of Gastroenterology Director, UCSD IBD Center La Jolla, California, USA Learning
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationDefinitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
More informationIl ruolo degli anticorpi anti farmaco nella pratica clinica
Il ruolo degli anticorpi anti farmaco nella pratica clinica Daniela Pugliese, MD IBD Unit Complesso Integrato Columbus Gemelli Hospital Catholic University Foundation, Rome - Italy Therapeutic Drug monitoring
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Francis A. Farraye, MD, MSc, FACG Professor of Medicine Clinical Director, Section of Gastroenterology Boston University School of Medicine Boston,
More informationHighlights of DDW 2015: Crohn s disease
Highlights of DDW 2015: Crohn s disease Mark S. Silverberg, MD, PhD, FRCPC Associate Professor of Medicine, University of Toronto Staff Gastroenterologist, Mount Sinai Hospital Senior Investigator, Lunenfeld-Tanenbaum
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationDrug Level Monitoring in IBD. Objectives
Drug Level Monitoring in IBD Corey A. Siegel, MD, MS Director, Dartmouth-Hitchcock IBD Center Associate Professor of Medicine, Geisel School of Medicine at Dartmouth Objectives Review non-biologic drug
More informationTo help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture,
To help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture, click Options in the Message Bar, and then click Enable
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationImplementation of disease and safety predictors during disease management in UC
Implementation of disease and safety predictors during disease management in UC DR ARIELLA SHITRIT DIGESTIVE DISEASES INSTITUTE SHAARE ZEDEK MEDICAL CENTER JERUSALEM Case presentation A 52 year old male
More informationΑπό τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών. Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων
Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων Conflict of interest By means of this, the speaker confirms that
More informationCAG Symposium: Management of IBD in 2018
CAG Symposium: Management of IBD in 2018 Waqqas Afif, MD, M. Sc., FRCPC, Associate Professor, Department of Medicine Division of Gastroenterology McGill University Health Center X X X X X CanMEDS Roles
More informationOptimal Use of Immunomodulators and Biologics
3/17/214 Optimal Use of Immunomodulators and Biologics Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota, U.S.A. Loftus Disclosures
More informationCROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM
CROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM Crohn's Disease Ulcerative Colitis Steroids x 2 No prior AZA/6-MP Biologic Agent AZA/6-MP STEP-UP MANAGEMENT APPROACH Advantages Patients attain remission
More informationPersonalized Medicine: IBD
Use of Anti-TNF Antibodies and Other Serologies for Managing IBD Christopher J. Shepela, MD, MS Assistant Professor of Medicine University of Minnesota Medical Director at Digestive Disease Center at Regions
More informationTreatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG
Treatment of Inflammatory Bowel Disease Michael Weiss MD, FACG What is IBD? IBD is an immune-mediated chronic intestinal disorder, characterized by chronic or relapsing inflammation within the GI tract.
More informationCrohn s
Crohn s Disease David T. Rubin, MD, AGAF Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology, and Nutrition Co-Director, Digestive Diseases Center @IBDMD Disclosures
More informationPrimary & Secondary Care Inflammatory Bowel Disease Pathway February 2018
South East London Area Prescribing Committee: Primary & Secondary Care Inflammatory Bowel Disease Pathway February 2018 Developed by: South East London IBD Pathway Development Group Approved: February
More informationOptimizing the treatment of IBD through use of therapeutic drug monitoring
Optimizing the treatment of IBD through use of therapeutic drug monitoring Adam S. Cheifetz Director, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center Associate Professor of
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationJoin the conversation at #IBDNEWSDDW
1 Join the conversation at #IBDNEWSDDW 2 Connect to Our Network Connect to the free GiHF network, via Wi-Fi Open GiHF.com To ask a question, get more information, or view slides, click Quick Join at the
More informationTherapeutic Drug Monitoring και ΙΦΝΕ το 2018
Therapeutic Drug Monitoring και ΙΦΝΕ το 2018 TDM: Ναι το χρειαζόμαστε, σε όλους και πάντοτε Κωνσταντίνος Κατσάνος Conflict of interest By means of this, the speaker confirms that he receives honoraria
More informationNEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL
NEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL CROHN S DISEASE Chronic disease of uncertain etiology Etiology- genetic, environmental, and infectious Transmural
More informationSevere IBD: What to Do When Anti- TNFs Don t Work?
Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and
More informationWHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY?
WHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY? Siew Ng, Professor MBBS, FRCP, (Lon, Edin), PhD (Lond), AGAF, FHKCP, FHKAM (medicine) Department of Medicine and Therapeutics Chinese University
More informationAAA Study. Dr Antony Friedman IBD Fellow, The Alfred Hospital Melbourne, Australia
AAA Study Use of Adjunctive Allopurinol in Azathioprine / 6-Mercaptopurine Non-Responders to Optimise 6-Thioguanine Nucleotide Production and Improve Clinical Outcomes Dr Antony Friedman IBD Fellow, The
More informationBiologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA
Biologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA Overview Indications and Drug Selection Contraindications
More informationDr. Elmer Schabel, MD. Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany (No conflicts of interest)
EMA workshop on the development of new medicinal products for the treatment of ulcerative colitis and Crohn s disease Overview of authorised medicines for IBD in Europe - previous regulatory positions
More informationPersonalized Medicine. Selecting the Right First-line Biologic Agent. Gene Expression Profiles Crohn s Disease. The Right Treatment
Personalized Medicine Selecting the Right First-line Biologic Agent William Tremaine, M.D. Maxine and Jack Zarrow Professor Mayo Clinic Rochester, MN, USA The Right Treatment Pretreatment Genomic Analysis
More informationSlide 1 Medications in inflammatory bowel disease a primer for health care providers. Slide 2. Slide 3 Theory of pathogenesis. IBD - epidemiology
Slide 1 Medications in inflammatory bowel disease a primer for health care providers Athos Bousvaros, MD Associate director Inflammatory Bowel Disease Center Boston Children s Hospital 617 355 2962 Slide
More informationIs top-down therapy a more effective alternative to conventional step-up therapy for Crohn s disease?
REVIEW ARTICLE Annals of Gastroenterology (2018) 31, 1-12 Is top-down therapy a more effective alternative to conventional therapy for Crohn s disease? Jonathan Jenkin Tsui a, Hien Q. Huynh b Edinburgh
More informationINFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL
INFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL A. Hillary Steinhart, MD MSc FRCP(C) Medical Lead, Mount Sinai Hospital IBD Centre Professor of Medicine University
More informationProgress in Inflammatory Bowel Disease
Progress in Inflammatory Bowel Disease Gary R Lichtenstein, MD Director, Center for IBD University of Pennsylvania School of Medicine Hospital of the University of PA Philadelphia, PA Disclosure Research,
More informationGionata Fiorino VEDOLIZUMAB E IBD. Un nuovo target terapeutico
Gionata Fiorino VEDOLIZUMAB E IBD Un nuovo target terapeutico Anti cell adhesion molecules Danese S, NEJM 2011 6 Steps leukocyte recruitment Fiorino G. et al. 2010 Vedolizumab Blocks Fewer Biological Pathways
More informationPreventing post-operative recurrence
Oxford Inflammatory Bowel Disease MasterClass Preventing post-operative recurrence Dr Oliver Brain Oxford Disclosures Presented at IEE, Oxford 2013 AbbVie sponsored meeting Talk Outline Risk factors for
More informationIBD Biologicals and Novel therapeutic regimes. Dr S K Sinha Additional Professor Department of Gastroenterology PGIMER, Chandigarh
IBD Biologicals and Novel therapeutic regimes Dr S K Sinha Additional Professor Department of Gastroenterology PGIMER, Chandigarh 1 Treatment aims in IBD Traditional treatment goals of IBD Control of symptoms?improvement
More informationManagement of Refractory Crohn s Disease
Management of Refractory Crohn s Disease @IBDMD David T. Rubin, MD, FACG, FASGE Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition Disclosures Consultant
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Sunanda Kane, MD, FACG Professor of Medicine Department of Gastroenterology and Hepatology Mayo Clinic Rochester, MN In my lecture today, I will be
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: Feb. 14, 2018 Last Revised: April 1, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: June 9, 2019* Last Revised: Feb. 12, 2019 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationImproving outcome of Inflammatory Bowel Disease in children
Improving outcome of Inflammatory Bowel Disease in children Dinesh Pashankar, MD Pediatric Gastroenterologist Director- Pediatric IBD program Yale University School of Medicine Pediatric Gastroenterology
More informationManagement of Moderate to Severe Ulcerative Colitis
Management of Moderate to Severe Ulcerative Colitis Neilanjan Nandi, MD Assistant Professor of Medicine Associate Program Director Division of Gastroenterology Drexel University College of Medicine Hahnemann
More informationIBD in teenagers Biological and Transition
IBD in teenagers Biological and Transition Dr Warren Hyer Consultant Paediatric Gastroenterologist St Mark s Hospital Chelsea and Westminster Hospital Conflict of Interest None to declare Fee for presentation
More informationNew Perspectives on the Diagnosis and Management of IBD. Disclosures
New Perspectives on the Diagnosis and Management of IBD Joel R. Rosh, MD Director, Pediatric Gastroenterology Goryeb Children's Hospital/Atlantic Health Professor of Pediatrics Icahn School of Medicine
More informationNew Directions on Therapeutic Drug Monitoring in IBD
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationSTELARA (ustekinumab) Clinical Study Report CNTO1275CRD3001
SYNOPSIS Name of Sponsor/Company Janssen Research & Development* Name of Investigational Product STELARA (ustekinumab) * Janssen Research & Development is a global organization that operates through different
More informationAnti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis
Anti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis University, 1st Department of Medicine Budapest June 13-15,
More informationOptimizing Therapies for Severe Ulcerative Colitis October 19, 2014
Optimizing Therapies for Severe Ulcerative Colitis October 19, 2014 Ellen J. Scherl, MD, FACP, FACG, AGAF, FASGE, NYSGEF Director Jill Roberts Center for Inflammatory Bowel Disease Jill Roberts IBD Research
More informationIBD Case Studies. David Rowbotham. Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital
IBD Case Studies David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust
More informationPEDIATRIC INFLAMMATORY BOWEL DISEASE
PEDIATRIC INFLAMMATORY BOWEL DISEASE Alexis Rodriguez, MD Pediatric Gastroenterology Advocate Children s Hospital Disclosers Abbott Nutrition - Speaker Inflammatory Bowel Disease Chronic inflammatory disease
More information